Autoimmune Disorders Conference - All PresentationsOriginal Date: June 11-12, 2022This discounted package includes all of the individual presentations from the conference, which are listed below.12.0 CEUs (including 7.75 general, 4.0 pharmacy, and 0.25 cultural competency) approved by OBNM
Autoimmunity: The Endocrine - Autoimmune Connection - A Holistic Approach to Assessment and TreatmentPresenter: Paul Anderson, NMDOriginal Date: June 11, 2022We have noticed for decades connections between endocrine imbalances and autoimmunity in our chronically ill patients. Often the question “Is it cause or effect we are seeing?”. The past 7-10 years have shown an expansion in peer-reviewed data and understanding about the interrelationship between autoimmunity and endocrine function that matches our past clinical experience. In this presentation Dr. Anderson will review the data and also give clinical application for the crossovers between autoimmunity and the main (not all) hormonal players including Thyroid, Corticoids, Estrogen, Progesterone, Testosterone. In addition, brief discussion in regard to the role of Insulin, Diet, and other corollary factors will be included.1.5 CEUs (including 0.5 general and 1.0 pharm) approved by OBNM- Naturopathic Approach to PANS and PANDASPresenter: Jill Crista, NDOriginal Date: June 11, 2022What trips the trigger toward autoimmunity and why the brain? Two very important questions tounderstand in order to address PANDAS and PANS. This talk will focus on those very questions. I’ll describe the mechanisms causing changes in the brains of kids with PANDAS and PANS, as well as some targets of treatment.1.5 CEUs (including 1.0 general and 0.5 pharm)approved by OBNM
- Autoimmunity and Chronic PainPresenter: Chris Kleronomos, DAOM, FNP, LAc, MScOriginal Date: June 11, 2022This lecture will explore the relationship between autoimmune disorders and chronic pain. It will focus on the development of centralized pain syndromes and the distinction between peripheral and structural pain versus centrally mediated pain, as well as the commonly associated constellation of symptoms. During this lecture standard diagnosis as well as clinical diagnosis will be discussed in context to chronic pain utilizing phenotypical differentiations for central pain syndromes. A comprehensive approach to treatment will be reviewed inclusive of both standard of care, naturopathic and experimental interventions.1.5 CEUs (including 1.00 general and 0.5 pharm)approved by OBNM
- Post Covid Immunology and Pharmacology ReviewPresenter: Brice Thompson, NDOriginal Date: June 11, 2022This presentation will update what we know about possible immune responses to COVID. Next, the talk will compare the two main vaccines available in the U.S. as well as discuss what is currently understood about the development of immunologic memory to both the vaccines and natural infection. Lastly, the talk will then transition into a review of potential etiologies behind post-acute sequelae of SARS-CoV-2 infection (PASC) and current treatment guidelines. Lastly, the talk will cover what pharmacologic treatments are currently available for CoVID-19 and their current guidelines of use.1.5 CEUs (including 0.75 general and 0.75 pharm)approved by OBNM
- Lyme, Tick Borne Infections and Autoimmunity: The Complex Puzzle?Presenter: Jaquel Patterson, NDOriginal Date: June 12, 2022This seeks to be a cohesive examination of autoimmunity and tick borne infections with a focus on Lyme disease. Lyme disease has a complex symptomology, which means patients often arrive having navigated challenges getting appropriate medical supports. In this review and update we will look at this complex puzzle striving to understand demographic implications in diagnosis of tickborne disorders. In addition to a review of infections, Lyme disease, and their cascade potential in autoimmunity, we will also examine naturopathic interventions through clinical case review, looking especially at pain, hormones, coinfections and Lyme disease and their intersection.1.5 CEUs (including 1.25 general and 0.25 CC) approved by OBNM
- Hashimoto's Disease in Preconception, Pregnancy and Post-partumPresenter: Kate Rothwell, NDOriginal Date: June 12, 2022Hashimoto's Disease is the most common autoimmune condition in women of child bearing age and presents unique challenges through preconception, pregnancy and beyond. This lecture will review proper assessment and monitoring for Hashimoto's patients through their fertility journey, as well as how this condition can affect ovarian reserve, miscarriage rates, birth outcomes, and post partum conditions including post partum anxiety/depression and post partum thyroiditis. Finally, we will explore evidenced based treatment options. You will leave this lecture with a solid understanding of how Hashimoto's affects pregnancy and learn how we can best support our patients at each stage of their journey.1.5 CEUs (including 1.25 general and 0.25 pharm)approved by OBNM
- Autoimmune GlomerulonephritisPresenter: Eric Yarnell, NDOriginal Date: June 12, 2022Type II and III hypersensitivity and other autoimmune conditions are a significant cause of kidney disease around the world, most notably IgA nephropathy and lupus nephritis. Less common problems include membranous and membranoproliferative glomerulonephritis. The naturopathic approach to diagnosis and management of patients with these conditions, as well as autoimmune vasculitides that commonly cause autoimmune kidney damage, will be discussed. Case studies will be used to highlight real-world approaches and outcomes.1.5 CEUs (including 0.75 general and 0.75 pharm)approved by OBNM
Mitolongevity and AutoimmunityPresenter: Chris Meletis, NDOriginal Date: June 12, 2022The presentation will provide an overview of the role of the mitochondria for immune function; cellular energetics with wide ranging affect inflammation, adrenal and thyroid function and cellular integrity. A review of the peer-review literature and ways to support mitochondrial function and cellular performance will be presented.1.5 CEUs (including 1.25 general and 0.25 pharm) approved by OBNM
